InspireMD launches new $75M ATM stock program
InspireMD, Inc. entered a new Equity Distribution Agreement with BTIG, LLC allowing it to sell, from time to time at its option, up to $75,000,000 of common shares in an at-the-market offering under its existing Form S-3 registration.
Rhea-AI Filing Summary
InspireMD, Inc. entered a new Equity Distribution Agreement with BTIG, LLC allowing it to sell, from time to time at its option, up to $75,000,000 of common shares in an at-the-market offering under its existing Form S-3 registration.
BTIG will act as sales agent and may receive a commission of up to 3.0% of gross proceeds. InspireMD currently plans to use any net proceeds for operations, including research and development, sales and marketing, working capital and other general corporate purposes. On the same date, the company terminated its prior at-the-market equity distribution agreement with Piper Sandler, under which 1,361,519 shares had been sold, and incurred no termination penalties.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 8.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
New ATM capacity: $75,000,000
Sales agent commission: 3.0% of gross proceeds
Prior ATM capacity: $75,000,000
+1 more
4 metrics
New ATM capacity
$75,000,000
Maximum common stock that may be sold through BTIG under Equity Distribution Agreement
Sales agent commission
3.0% of gross proceeds
Maximum commission payable to BTIG on shares sold
Prior ATM capacity
$75,000,000
Maximum shares value registered under terminated Piper Sandler equity distribution agreement
Shares sold under prior ATM
1,361,519 shares
Common stock sold pursuant to the Piper Sandler equity distribution agreement
Key Terms
Equity Distribution Agreement, at the market offering, Registration Statement on Form S-3, prospectus supplement, +1 more
5 terms
Equity Distribution Agreement financial
"entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with BTIG, LLC"
An equity distribution agreement is a formal plan between a company and financial institutions to sell newly issued shares of the company's stock to investors over a period of time. It helps the company raise money gradually, similar to filling a container with water in stages, rather than all at once. For investors, it provides an organized way to buy shares and can influence the stock's supply and price.
at the market offering financial
"deemed to be an “at the market offering” as defined in Rule 415(a)(4)"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
Registration Statement on Form S-3 regulatory
"pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-286309)"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
prospectus supplement regulatory
"Pursuant to the prospectus supplement relating to the Offering, dated as of April 3, 2026"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
indemnification rights financial
"The Company has agreed to provide BTIG with customary indemnification rights with respect to certain liabilities"
FAQ
What did InspireMD (NSPR) announce regarding a new equity distribution program?
InspireMD entered an Equity Distribution Agreement with BTIG, LLC to sell up to $75,000,000 of common stock in an at-the-market offering under its Form S-3 registration, with BTIG acting as sales agent on commercially reasonable efforts terms.
How much stock can InspireMD (NSPR) sell under the new BTIG agreement?
The company may offer and sell up to $75,000,000 of common shares through or to BTIG. Sales may occur from time to time at market-related prices as an at-the-market offering under a prospectus supplement dated April 3, 2026.
What fees will InspireMD (NSPR) pay BTIG under the Equity Distribution Agreement?
BTIG is entitled to a commission of up to 3.0% of the gross proceeds from shares sold under the agreement. BTIG must use commercially reasonable efforts consistent with its normal trading and sales practices and applicable Nasdaq and regulatory rules.
How does InspireMD (NSPR) plan to use net proceeds from the new ATM program?
InspireMD currently intends to use any net proceeds for operations, including research and development, sales and marketing, working capital and other general corporate purposes, and for any additional purposes that may be described in future prospectus supplements.
What happened to InspireMD’s prior at-the-market offering with Piper Sandler?
Effective April 3, 2026, InspireMD terminated its prior equity distribution agreement and related prospectus with Piper Sandler. The company had sold 1,361,519 shares under that program and is not subject to any termination penalties following this termination.
AI-generated analysis. How Rhea-AI works. Not financial advice.
